Document Type
Article
Publication Date
8-18-2020
Publication Title
Oncotarget
Abstract
BACKGROUND: Brain metastases are a significant cause of mortality and morbidity for patients with melanoma. We hypothesize that the development of brain metastases may be explained by molecular heterogeneity between primary cutaneous melanoma (PCM) or extracranial (ECM) and brain (MBM) melanoma metastases.
MATERIALS AND METHODS: We compared next-generation sequencing, tumor mutational burden (TMB), and immunohistochemical staining for PD-L1 expression, among 132 MBM, 745 PCM, and 1190 ECM.
RESULTS: The most common genetic alterations among MBM included: BRAF (52.4%), NRAS (26.6%), CDKN2A (23.3%), NF1 (18.9%), TP53 (18%), ARID2 (13.8%), SETD2 (11.9%), and PBRM1 (7.5%). Four genes were found with higher frequency among MBM compared to PCM or ECM: BRAF (52.4% v 40.4% v 40.9%), SETD2 (11.9% v 1.9% v 3.9%), PBRM1 (7.5% v 1.6% v 2.6%), and DICER1 (4.4% v 0.6% v 0.4%). MBM showed higher TMB (
CONCLUSIONS: Our findings suggest a unique molecular profile for MBM, including higher rates of BRAF mutations, higher TMB and higher PD-L1 expression, and also implicate chromatin remodeling in the pathogenesis of MBM.
Clinical Institute
Cancer
Department
Oncology
Recommended Citation
In, Gino K; Poorman, Kelsey; Saul, Michelle; O'Day, Steven; Farma, Jeffrey M; Olszanski, Anthony J; Gordon, Michael S; Thomas, Jacob S; Eisenberg, Burton; Flaherty, Lawrence; Weise, Amy; Daveluy, Steven; Gibney, Geoffrey; Atkins, Michael B; and Vanderwalde, Ari, "Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases." (2020). Articles, Abstracts, and Reports. 3659.
https://digitalcommons.providence.org/publications/3659
